EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting the Sirtuin–1/PPAR–Gamma Axis, RAGE/HMGB1/NF-κB Signaling, and the Mitochondrial Functions by Canagliflozin Augments the Protective Effects of Levodopa/Carbidopa in Rotenone-Induced Parkinson’s Disease

Mennatallah A Elkady, Ahmed M Kabel iD, Lamees M Dawood, Azza I Helal, Hany M Borg, Hanan Abdelmawgoud Atia, Nesreen M Sabry, Nouran M Moustafa, El-Shaimaa A Arafa iD, Shuruq E Alsufyani iD, Hany H Arab

Medicina · 2024

DOI: 10.3390/medicina60101682 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicina, 2024. Verfasst von Mennatallah A Elkady und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology Department, Faculty of Medicine, Tanta University, Tanta 31527, Egypt. Hauptthemen laut MEDLINE: Levodopa, Carbidopa, Rotenone, Sirtuin 1. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taif University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: Parkinson’s disease (PD) is a pathological state characterized by a combined set of abnormal movements including slow motion, resting tremors, profound stiffness of skeletal muscles, or obvious abnormalities in posture and gait, together with significant behavioral changes. Until now, no single therapeutic modality was able to provide a complete cure for PD. This work was a trial to assess the immunomodulatory effects of canagliflozin with or without levodopa/carbidopa on rotenone-induced parkinsonism in Balb/c mice. Materials and Methods: In a mouse model of PD, the effect of canagliflozin with or without levodopa/carbidopa was assessed at the behavioral, biochemical, and histopathological levels.

Results

The combination of levodopa/carbidopa and canagliflozin significantly mitigated the changes induced by rotenone administration regarding the behavioral tests, striatal dopamine, antioxidant status, Nrf2 content, SIRT–1/PPAR–gamma axis, RAGE/HMGB1/NF-κB signaling, and mitochondrial dysfunction; abrogated the neuroinflammatory responses, and alleviated the histomorphologic changes induced by rotenone administration relative to the groups that received either levodopa/carbidopa or canagliflozin alone.

Conclusions

Canagliflozin may represent a new adjuvant therapeutic agent that may add value to the combatting effects of levodopa/carbidopa against the pathological effects of PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevodopaCarbidopaRotenoneSirtuin 1NF-kappa BHMGB1 ProteinCanagliflozinDisease Models, AnimalSignal TransductionMice, Inbred BALB CPPAR gammaAnimalsMiceParkinson DiseaseDrug CombinationsMaleMitochondriaReceptor for Advanced Glycation End Products

Stichwörter der Autor:innen

Parkinson’s diseasecanagliflozinlevodopa/carbidopamicepathophysiologysirtuin-1/PPAR-gamma axis

Substanzen

LevodopaCarbidopaRotenoneSirtuin 1NF-kappa BHMGB1 ProteinCanagliflozinPPAR gammaDrug Combinationscarbidopa, levodopa drug combination

Autor:innen und Institutionen

  • Pharmacology Department, Faculty of Medicine, Tanta University, Tanta 31527, Egypt.
  • Medical Biochemistry Department, Faculty of Medicine, Tanta University, Tanta 31511, Egypt.
  • Department of Histology and Cell Biology, Faculty of Medicine, Kafrelsheikh University, Kafrelsheikh 33516, Egypt.
  • Physiology Department, Faculty of Medicine, Kafrelsheikh University, Kafr El-Shaikh 33516, Egypt.
  • Department of Pharmacology and Toxicology, College of Pharmacy, University of Hail, Hail 2440, Saudi Arabia.
  • Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Al-Azhar University, Cairo 35527, Egypt.

ORCID-Profile: Ahmed M Kabel, El-Shaimaa A Arafa, Shuruq E Alsufyani

Förderung

  • Taif University

Zitieren

APA

Elkady, M. A., Kabel, A. M., Dawood, L. M., Helal, A. I., Borg, H. M., Atia, H. A., Sabry, N. M., Moustafa, N. M., Arafa, E. A., Alsufyani, S. E., & Arab, H. H. (2024). Targeting the Sirtuin–1/PPAR–Gamma Axis, RAGE/HMGB1/NF-κB Signaling, and the Mitochondrial Functions by Canagliflozin Augments the Protective Effects of Levodopa/Carbidopa in Rotenone-Induced Parkinson’s Disease. Medicina. https://doi.org/10.3390/medicina60101682

Vancouver

Elkady MA, Kabel AM, Dawood LM, Helal AI, Borg HM, Atia HA, et al. Targeting the Sirtuin–1/PPAR–Gamma Axis, RAGE/HMGB1/NF-κB Signaling, and the Mitochondrial Functions by Canagliflozin Augments the Protective Effects of Levodopa/Carbidopa in Rotenone-Induced Parkinson’s Disease. Medicina. 2024. doi:10.3390/medicina60101682

BibTeX
@article{Elkady2024,
  author = {Elkady, Mennatallah A and Kabel, Ahmed M and Dawood, Lamees M and Helal, Azza I and Borg, Hany M and Atia, Hanan Abdelmawgoud and Sabry, Nesreen M and Moustafa, Nouran M and Arafa, El-Shaimaa A and Alsufyani, Shuruq E and Arab, Hany H},
  title = {Targeting the Sirtuin–1/PPAR–Gamma Axis, RAGE/HMGB1/NF-κB Signaling, and the Mitochondrial Functions by Canagliflozin Augments the Protective Effects of Levodopa/Carbidopa in Rotenone-Induced Parkinson’s Disease},
  journal = {Medicina},
  year = {2024},
  doi = {10.3390/medicina60101682}
}
Kostenlos starten →